• Currently according to Mielke and colleagues drugs with US

  2020-10-08

  

  Currently, according to Mielke and colleagues [103], drugs with US Food and Drug Administration (FDA) approval for Alzheimer therapy include the following: galantamine (Razadyn®, 4aS,6R,8aS-5,6,9,10,11,12- hexahydro- 3-methoxy- 11-methyl- 4aH [1], benzofuro[3a,3,2-ef] [2] benzazepin- 6-ol), rivastig

• Recent studies have shown that

  2020-10-08

  

  Recent studies have shown that some CLC genes participate in plant salt tolerance and have speculated that they function by mediating Cl− transport across the tonoplast. For instance, AtCLCc, a vacuolar anion transporter, is shown to be involved in the regulation of stomatal movement and to contribu

• To avoid the difficulty of the nonsmooth constraints a

  2020-10-08

  

  To avoid the difficulty of the nonsmooth constraints, a sequence of smooth problems by using smoothing functions have been progressively approximated this nonsmooth problem. To date, there have been many smoothing functions, such as perturbed Fischer–Burmeister (FB), Chen–Harker–Kanzow–Smale (CHKS),

• In brief while previous studies have evaluated

  2020-10-08

  

  In brief, while previous studies have evaluated the individual roles of VDR and ER signaling pathways in breast cancer, in the present study we performed an in silico approach for comparative evaluation of these pathways. Considering the complex interaction networks in the context of cancer, such co

• Determination of relative potency EC by

  2020-10-08

  

  Determination of relative potency (EC50) by dose response assays in vitro is subject to the same sources of variability as determination of affinity, since the EC50 and Hill slope of the dose response curve are highly dependent on the binding of ligand to a competing receptor that may be present, an

• br Benefits and risks of traditional combined oestrogen prog

  2020-10-08

  

  Benefits and risks of traditional combined oestrogen–progestogen HRT regimens Combined oestrogen–progestogen regimens were developed to reproduce the short- and long-term benefits of oestrogen replacement therapy (ERT) and to simultaneously provide appropriate protection against oestrogen-related

• Enolase is an example of a moonlighting

  2020-10-06

  

  Enolase is an example of a moonlighting protein that displays multiple biological actions, including plasminogen, laminin, fibronectin, mucin and cytokeratin binding properties. It has also been described as a complement-evasion protein and as a protein capable of inducing neutrophil trap formation.

• CXCR is not only critical in the

  2020-10-06

  

  CXCR5 is not only critical in the B cell lineage in FL. A high proportion of CXCR5-expressing follicular helper T cells (TFH) were observed in FL but not in closely related DLBCL [141] and further investigation revealed that FL regulatory T cells (Tregs) used a CXCL13-CXCR5 autocrine loop for positi

• With respect to bone metabolism and ossification

  2020-10-06

  

  With respect to ‘bone metabolism and ossification’-related genes, treatment of SaOS-2 osteoblast-like prexasertib with MS-10 up-regulated IGFBP-4, TG2, and SOST. Up-regulation of IGFBP-4 in SaOS-2 cells inhibits DNA and protein synthesis induced by IGF-1 (Kudo et al., 1995, Kudo et al., 1996). In a

• As part of a program to explore the key binding

  2020-10-05

  

  As part of a program to explore the key binding interactions between the core of 1 and DGAT-1 a systematic analysis of the aminopyrimidine subunit was initiated. A potential approach to improving passive permeability within this series would be to increase lipophilicity via incorporation of substitu

• In mammals ribonucleotide reductase RNR is a unique enzyme

  2020-10-01

  

  In mammals, ribonucleotide reductase (RNR) is a unique enzyme that catalyzes the rate-limiting step of de novo synthesis of deoxyribonucleoside triphosphates (dNTPs).7, 8 Mammalian RNR consists of two homodimer subunits: the large catalytic dimer RRM1 and the small regulatory dimer RRM2 or RRM2B. An

• br Clinical potential of ET receptor biased

  2020-09-30

  

  Clinical potential of ET receptor biased ligands Is there a clinical need for ET receptor biased ligands? Evidence is strongest from research in epithelial ovarian cancer demonstrating that ET-1 stimulated ETA-mediated β-arrestin signalling leads to activation of the oncogenic mediator NF-κB [21]

• Cucurbitacin I br Protein protein interactions of

  2020-09-30

  

  Protein-protein interactions of LEI/L-DNase II and the control of cell death Evolutionary tips The serpin inhibitory mechanism is extremely well adapted to evolutionary changes because a single amino Cucurbitacin I substitution in the RSL can led to the inhibition of a totally different prote

• Fmoc-Arg(Pbf)-OH A prominent example of such enzyme is the p

  2020-09-30

  

  A prominent example of such enzyme is the proteasome, a highly promising target not only in cancer, but also in inflammatory and autoimmune diseases. Circulating proteasomes and respective anti-proteasome autoantibodies were detected in serum samples from patients with autoimmune diseases such as mu

• Fmoc-Gly-OPfp Recent studies have also uncovered additional

  2020-09-30

  

  Recent studies have also uncovered additional roles for E2 enzymes and E2~Ub conjugates in modulating the activity of deubiquitinating enzymes (DUBs), such as OTUB1 (Juang et al., 2012, Wiener et al., 2013, Wiener et al., 2012). Interestingly, OTUB1 has also been shown to associate and modulate the

15660 records 757/1044 page Previous Next First page 上5页 756757758759760 下5页 Last page